比利时观察性生存数据(2004-2017年发病)与十二种癌症适应症创新肿瘤药物支出
该队列研究利用比利时癌症登记处125,692例患者(12种癌症适应症,发病期2004-2017年)的报销与生存数据,评估肿瘤药物支出变化与总生存改善的关系。结果显示几乎所有适应症的总支出和平均治疗费用均增加,但总生存概率和中位生存时间的改善结果不一,仅非小细胞肺癌和慢性髓性白血病3年生存概率绝对改善约10%,约半数其他适应症改善有限或缺失。
要点
- 几乎所有适应症的肿瘤药物总支出和平均治疗费用在2004-2017年间增加。
- 非小细胞肺癌和慢性髓性白血病3年生存概率绝对改善约10%。
- 约半数其他适应症的生存改善有限或缺失。
核心结论
- 比利时观察性数据表明,假设「创新」肿瘤药物总能带来生存改善的价值往往不合理。
- 文献强调使用替代终点的问题,以及上市批准时或上市后阶段缺乏比较证据证明肿瘤药物在生存和生活质量方面的附加价值。
- 作者建议在上市前阶段开展适合注册目的的比较研究,以辅助报销决策并支持医生和患者做出治疗决策。
研究设计与样本
- 队列研究,使用比利时癌症登记处125,692例患者数据,涵盖12种癌症适应症,发病期为2004-2017年,链接报销和生存数据。
- 该数据可靠地代表比利时情况。
- 审查指标包括1至5年观察生存概率、中位生存时间、肿瘤药物支出和每患者平均肿瘤药物费用。
主要发现
- 在几乎所有适应症中,肿瘤药物总支出和平均治疗费用在2004-2017年间增加。
- 总生存概率和中位生存时间的演变结果不一。
- 非小细胞肺癌和慢性髓性白血病3年生存概率绝对改善约10%。
- 约半数其他适应症的改善有限或甚至缺失。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Food and Drug Administration and European Medicines Agency typically approve market access for cancer drugs based on surrogate end-points, which do not always translate into substantiated improvements in outcomes that matter the most to patients, i.e. survival and quality of life. These drugs often, also, have a high price tag. We assessed whether there was an increase in cancer drug expenditure for a broad selection of indications, and whether this correlates with increased overall survival. METHODS: This cohort study used Belgian Cancer Registry data from 125,692 patients (12 cancer indications, incidence period 2004-2017), which was linked to reimbursement and survival data. This reliably represents the Belgian situation. One-to-five year observed survival probability, median survival time, oncology drug expenditure and mean oncology drug cost per patient were reviewed. FINDINGS: In almost all indications, total expenditure and average treatment cost for oncology drugs increased over the years (2004-2017). In contrast, mixed findings are observed for the evolution in overall survival probability and median survival time. While an absolute improvement in the 3-year survival probability of about 10% is noticed in non-small-cell lung cancer and chronic myeloid leukaemia, improvements in about half of the other indications are limited or even absent. INTERPRETATION: The Belgian observational data indicate that assuming 'innovative' oncology drugs always add value in terms of improved survival is often unjustified. The literature also highlights the problem of using surrogate end-points, and the lack of comparative evidence showing an added value of oncology drugs for both survival and quality of life at market approval or during the post-marketing phase. Comparative studies should be conducted in the pre-marketing phase that are suitable for registration purposes, aid reimbursement decisions and support physicians and patients when making treatment decisions.
引用
- Neyt M, Devos C, Thiry N, et al. Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indications. Eur J Cancer. 2023. PMID: 36731327. doi:10.1016/j.ejca.2022.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。